Clinical Trial Update: Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) [Phase 2, Phase 3]

View source ↗

Summary

An ongoing Phase 2/3 trial in an expanded Lung-MAP study evaluating cemiplimab added to standard treatment for advanced non-small cell lung cancer after prior p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Libtayo (cemiplimab) (cemiplimab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2, Phase 3 | Status: RECRUITING